Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sensei Biotherapeutics Inc (SNSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNSE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32.5
1 Year Target Price $32.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.39% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.46M USD | Price to earnings Ratio - | 1Y Target Price 32.5 |
Price to earnings Ratio - | 1Y Target Price 32.5 | ||
Volume (30-day avg) 2 | Beta 0.26 | 52 Weeks Range 5.00 - 17.40 | Updated Date 08/15/2025 |
52 Weeks Range 5.00 - 17.40 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.29 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.24 | Actual -3.91 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.75% | Return on Equity (TTM) -67.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16609325 | Price to Sales(TTM) - |
Enterprise Value -16609325 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 1261290 | Shares Floating 828302 |
Shares Outstanding 1261290 | Shares Floating 828302 | ||
Percent Insiders 34.14 | Percent Institutions 6.19 |
Upturn AI SWOT
Sensei Biotherapeutics Inc
Company Overview
History and Background
Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of next-generation immunotherapies for cancer. Founded in 2017, it utilizes its ImmunoPhage platform to generate immunotherapies that drive robust and complete responses in cancer patients.
Core Business Areas
- Immuno-oncology Drug Development: Focuses on developing cancer immunotherapies using the ImmunoPhage platform, targeting various solid tumors.
Leadership and Structure
The company has a leadership team with experience in oncology drug development and business management. Key executives lead research, clinical development, and corporate strategy.
Top Products and Market Share
Key Offerings
- SNS-101: A VISTA-blocking antibody designed to unlock anti-tumor immunity. Currently in clinical trials for solid tumors. Market share is not applicable as it is still in clinical development. Competitors include companies developing other VISTA-blocking therapies such as JTX-8064 from Compugen (CMPG) and others in earlier stages.
- SNS-VISTA Inhibitors: Sensei is developing a range of VISTA inhibitors. Market share data is not applicable for these clinical programs. Competitors include companies developing other VISTA-blocking therapies such as JTX-8064 from Compugen (CMPG) and others in earlier stages.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, with significant investments in novel therapeutic approaches. Competition is intense, and success depends on demonstrating clinical efficacy and safety.
Positioning
Sensei Biotherapeutics is positioned as an innovator in the immuno-oncology space with its unique ImmunoPhage platform. The company's competitive advantage lies in its potential to stimulate robust anti-tumor immune responses.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. Sensei Biotherapeutics is positioned to capture a portion of this market by developing innovative immunotherapies targeting solid tumors. Currently the market is made up of big pharma companies like Merck (MRK), Bristol Myers Squibb (BMY) and Roche (RHHBY).
Upturn SWOT Analysis
Strengths
- Novel ImmunoPhage platform
- Focus on VISTA inhibition
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Reliance on clinical trial success
- High R&D costs
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of ImmunoPhage platform to new targets
- Positive clinical trial results
- FDA fast-track designation
Threats
- Competition from established immuno-oncology therapies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- CMPG
- RHHBY
Competitive Landscape
Sensei Biotherapeutics faces intense competition from established pharmaceutical companies with approved immuno-oncology therapies. Its competitive advantage lies in its novel platform and focus on VISTA inhibition, but it needs to demonstrate clinical efficacy to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of the ImmunoPhage platform and the advancement of SNS-101 through clinical trials.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and potential partnerships.
Recent Initiatives: Recent initiatives include the enrollment of patients in clinical trials for SNS-101 and the exploration of new targets for the ImmunoPhage platform.
Summary
Sensei Biotherapeutics is a development-stage company with a promising ImmunoPhage platform and a focus on VISTA inhibition. The company's success hinges on the outcome of its clinical trials. Strong intellectual property and an experienced leadership team are key strengths, while limited financial resources and competition from established players are challenges. Positive clinical trial results and strategic partnerships are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data may be outdated. Investment decisions should be based on independent research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensei Biotherapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Mr. John K. Celebi M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.senseibio.com |
Full time employees 14 | Website https://www.senseibio.com | ||
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.